BRIEF published on 04/07/2026 at 07:05, 2 months 24 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 2 months 24 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 3 months 11 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 3 months 11 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 5 months 20 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 6 months 30 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 9 months 5 days ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 9 months 5 days ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 1 year 11 months ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 1 year 11 months ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 07/01/2026 at 03:15, 9 hours 14 minutes ago GLG Life Tech Corporation Announces 2026 AGM Voting Results
Published on 07/01/2026 at 01:00, 11 hours 29 minutes ago Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Published on 07/01/2026 at 00:00, 12 hours 29 minutes ago Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
Published on 06/30/2026 at 23:01, 13 hours 28 minutes ago NextSource Materials Provides Clarification on a Prior News Release
Published on 06/30/2026 at 22:30, 13 hours 59 minutes ago International Battery Metals Announces Change of Auditor
Published on 07/01/2026 at 12:05, 24 minutes ago FAIR PLAY MENARINI INTERNATIONAL AWARD: THE 30TH EDITION KICKS OFF
Published on 07/01/2026 at 12:05, 24 minutes ago EQS-Adhoc: Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights
Published on 07/01/2026 at 12:00, 29 minutes ago Linde Announces Second Quarter 2026 Earnings and Conference Call Schedule
Published on 07/01/2026 at 11:36, 53 minutes ago Emerald Horizon AG: Founder, CEO and Majority Shareholder Florian Wagner Commits EUR 20 Million in Equity Financing
Published on 07/01/2026 at 11:24, 1 hour 5 minutes ago EQS-Adhoc: HOCHTIEF Aktiengesellschaft: CIMIC acquires 100% interest in Thiess
Published on 07/01/2026 at 08:45, 3 hours 44 minutes ago Air Liquide invests over 170M USD in the U.S. to support SK hynix’s ambition to build a global AI memory ecosystem
Published on 07/01/2026 at 07:00, 5 hours 29 minutes ago BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK
Published on 06/30/2026 at 20:52, 15 hours 36 minutes ago Number of shares and voting rights - May 2026 (In French only)
Published on 06/30/2026 at 18:59, 17 hours 30 minutes ago SUEZ has successfully completed a €600 million green bond issuance
Published on 06/30/2026 at 17:45, 18 hours 44 minutes ago Carrefour completes the sale of Carrefour Romania to Paval Holding
